EP1778857A4 - DIRECT ACTIVATION OF ATIII IN FULL BLOOD AND PLASMA - Google Patents

DIRECT ACTIVATION OF ATIII IN FULL BLOOD AND PLASMA

Info

Publication number
EP1778857A4
EP1778857A4 EP05769136A EP05769136A EP1778857A4 EP 1778857 A4 EP1778857 A4 EP 1778857A4 EP 05769136 A EP05769136 A EP 05769136A EP 05769136 A EP05769136 A EP 05769136A EP 1778857 A4 EP1778857 A4 EP 1778857A4
Authority
EP
European Patent Office
Prior art keywords
atiii
plasma
direct activation
full blood
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05769136A
Other languages
German (de)
French (fr)
Other versions
EP1778857A1 (en
Inventor
David R Elmaleh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP1778857A1 publication Critical patent/EP1778857A1/en
Publication of EP1778857A4 publication Critical patent/EP1778857A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18Testing for antimicrobial activity of a material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81Protease inhibitors
    • G01N2333/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121Serpins
    • G01N2333/8128Antithrombin III
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
EP05769136A 2004-07-07 2005-07-07 DIRECT ACTIVATION OF ATIII IN FULL BLOOD AND PLASMA Withdrawn EP1778857A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58604304P 2004-07-07 2004-07-07
PCT/US2005/024046 WO2006014519A1 (en) 2004-07-07 2005-07-07 Direct activation of atiii in whole blood and plasma

Publications (2)

Publication Number Publication Date
EP1778857A1 EP1778857A1 (en) 2007-05-02
EP1778857A4 true EP1778857A4 (en) 2007-09-26

Family

ID=35787415

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05769136A Withdrawn EP1778857A4 (en) 2004-07-07 2005-07-07 DIRECT ACTIVATION OF ATIII IN FULL BLOOD AND PLASMA

Country Status (6)

Country Link
EP (1) EP1778857A4 (en)
JP (1) JP2008505912A (en)
CN (1) CN101014717A (en)
AU (1) AU2005269887A1 (en)
CA (1) CA2576173A1 (en)
WO (1) WO2006014519A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19836339B4 (en) 1998-08-11 2011-12-22 N.V. Nutricia carbohydrate mix
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
EP1721611A1 (en) * 2005-04-21 2006-11-15 N.V. Nutricia Nutritional supplement with oligosaccharides for a category of HIV patients
WO2008100258A1 (en) * 2007-02-14 2008-08-21 Academic Medical Center, University Of Amsterdam Intraperitoneal administration of antithrombin iii, related compositions and methods
CN101684646B (en) * 2008-09-27 2011-03-23 海洋石油工程股份有限公司 Height-adjustable cushion pier
US20200085849A1 (en) * 2017-05-18 2020-03-19 Elysium Health, Inc. Methods and compositions for improving sleep

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058638A2 (en) * 2001-01-26 2002-08-01 The General Hospital Corporation Serpin drugs for treatment of hiv infection and method of use thereof
WO2004100973A2 (en) * 2003-05-13 2004-11-25 The General Hospital Corporation Pharmaceutical compositions of antithrombin iii for the treatment of retroviral diseases.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058638A2 (en) * 2001-01-26 2002-08-01 The General Hospital Corporation Serpin drugs for treatment of hiv infection and method of use thereof
WO2004100973A2 (en) * 2003-05-13 2004-11-25 The General Hospital Corporation Pharmaceutical compositions of antithrombin iii for the treatment of retroviral diseases.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COOMBE D R ET AL: "LOW ANTICOAGULANT HEPARIN RETAINS ANTI-HIV TYPE 1 ACTIVITY IN VITRO", AIDS RESEARCH AND HUMAN RETROVIRUSES, MARY ANN LIEBERT, US, vol. 11, no. 11, 1995, pages 1393 - 1396, XP009033624, ISSN: 0889-2229 *
GEIBEN-LYNN RALF ET AL: "Purification of a modified form of bovine antithrombin III as an HIV-1 CD8+ T-cell antiviral factor", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 277, no. 44, 1 November 2002 (2002-11-01), pages 42352 - 42357, XP002288481, ISSN: 0021-9258 *
See also references of WO2006014519A1 *

Also Published As

Publication number Publication date
CA2576173A1 (en) 2006-02-09
CN101014717A (en) 2007-08-08
WO2006014519A1 (en) 2006-02-09
JP2008505912A (en) 2008-02-28
EP1778857A1 (en) 2007-05-02
AU2005269887A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
DE60327203D1 (en) COMBINATION OF AZELASTINE AND FLUTICASONE
DE602004032140D1 (en) TREATMENT DEVICE USING EXTRACTIVE GAS AND REACTIVE GAS
DE60319925D1 (en) Reduction of the outflow of particles in boreholes
EP1551324A4 (en) LIQUID PROCESSING SETS AND ORGANIZERS THEREFOR
ATE486091T1 (en) VEGF TRAPES AND THERAPEUTIC USES THEREOF
IL181779A (en) Class of therapeutic protein based molecules
EP1855833A4 (en) PLASMAS AND METHODS OF USE
DE602005017456D1 (en) Plasma display panel and manufacturing method thereof
DE602005027825D1 (en) AS AZHIBITORS OF JAK AND OTHER PROTEIN KINASES SUITABLE AZAINDOLE
DE602005007494D1 (en) AZAINDOLINHIBITORS OF MTP AND APOB
DE60328206D1 (en) WASHER WASHER AND WASHER
DE602005021589D1 (en) Multi-axis pressure sensor chip and multi-axis pressure sensor with it
EP1511736A4 (en) THERAPEUTIC MOLECULES AND METHODS - 1
EP1746902A4 (en) MULTILEKTIN AFFINICHROMATOGRAPHY AND USE THEREOF
DE60325158D1 (en) Turbomolecular pump and flange
DE60325967D1 (en) STIMULATION OF HEMATOPOIESE IN EX VIVO-ACTIVATED IMMUNOCELLS
DE602005022926D1 (en) HEAT ENHANCEMENT IN THE CRITICAL FIELD OF TRANSPARENT PLASTIC FIELD
DE10338270B4 (en) Variator and variator arrangement
ATE524183T1 (en) USE OF SANGLIFEHRIN IN HCV THERAPY
EP1738654A4 (en) SOLUTION AND GEL CONTAINING SOY PROTEIN
EP1778857A4 (en) DIRECT ACTIVATION OF ATIII IN FULL BLOOD AND PLASMA
ATE420081T1 (en) TRIFLUORMETHYLBENZAMIDE DERIVATIVES AND THERAPEUTIC USES THEREOF
PL377180A1 (en) The use of isoflavones and their derivatives in the treatment of mucopolysaccharidoses
DE602005022211D1 (en) SEVEN AND VISIBLE WITH BREAKTHROUGH DETECTOR
IL177435A0 (en) Expression of plasminogen and microplasminogen in duckweed

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20070829

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20071220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100202